Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative treatments for gastrointestinal diseases. Founded in 1998, Ironwood has made significant strides in the industry, particularly with its flagship product, Linzess (linaclotide), which addresses irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). With a strong presence in the US and expanding operations in key international markets, Ironwood is dedicated to improving patient outcomes through its unique approach to drug development. The company has established itself as a notable player in the gastrointestinal sector, leveraging its expertise to deliver effective therapies that meet unmet medical needs. Ironwood's commitment to innovation and patient care continues to drive its success in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Ironwood Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ironwood Pharmaceuticals, Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ironwood Pharmaceuticals, Inc.'s reported carbon emissions
Ironwood Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments in detail. However, the absence of documented reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly prioritises sustainability, Ironwood may consider establishing measurable targets and initiatives to align with industry standards and contribute to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ironwood Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
